Correlation of Serum Ethosuximide Levels with Clinical Effect
Correlation of clinical control with the serum concentration of phenobarbitone and phenytoin was reported for a group of patients by Buchthal and Svensmark (1959/ 1960) but wide use of serum concentrations did not begin until 1969 when Pippenger and Gillen reported the simultaneous, multiple determination of anti-epileptic drugs by gas-liquid chromatography. Subsequent to their report, the empirical improvement of seizure control by determining serum concentrations of anti-epileptic drugs has been widely used (Solow and Green, 1972; Green et al., 1973; Sherwin, Robb and Lechter, 1973). Nevertheless, skepticism remains among some physicians concerning the relationship of serum concentration to clinical effect because seizure frequency does not decrease in certain patients with high serum concentrations, even in the toxic range. Such patients are said to be refractory to the drug.
KeywordsNeurol Etho Clonazepam Phenobarbitone Barbital
Unable to display preview. Download preview PDF.
- Glazko, A. J., Dill, W. A.: Ethosuximide: Chemistry and methods for determination. In: Antiepileptic Drugs (eds. D. M. Woodbury, J. K. Penry, R. P. Schmidt), p. 413, New York: Raven Press 1972.Google Scholar
- Green, J. B., Hartlage, L., Solow, E., Baum, E.: Correlations between seizure frequency and serum anticonvulsant levels. Neurology 23, 405 (1973).Google Scholar
- Penry, J. K., Porter, R. J., Dreifuss, F. E.: Ethosuximide: Relation of plasma levels to clinical control. In: Antiepileptic Drugs (eds. D. M. Woodbury, J. K. Penry, R. P. Schmidt), p. 431. New York: Raven Press 1972.Google Scholar